COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

被引：0
|
作者：
Xiao, D. [1 ]
Zhu, S. [1 ]
Sun, W. [2 ]
Xuan, J. [3 ]
机构：
[1] Shanghai Centennial Sci Co Ltd, Shanghai, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.831
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIH31
引用
收藏
页码：S187 / S188
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [2] Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma
    Parikh, Neehar D.
    Singal, Amit G.
    Hutton, David W.
    CANCER, 2017, 123 (19) : 3725 - 3731
  • [3] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [4] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
  • [5] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
  • [6] Regorafenib as second-line therapy in hepatocellular carcinoma
    Duffy, Austin G.
    Greten, Tim F.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (03) : 141 - 142
  • [7] Regorafenib as second-line therapy in hepatocellular carcinoma
    Austin G. Duffy
    Tim F. Greten
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 141 - 142
  • [8] Hepatocellular Carcinoma: Successes with Regorafenib in Second-line Therapy
    Weiss, Johannes
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (05):
  • [9] Regorafenib promising second-line treatment in hepatocellular carcinoma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (08) : 446 - 446
  • [10] US COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO REGORAFENIB AND CABOZANTINIB IN SECOND LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
    Upadhyay, N.
    Mistry, R.
    Suri, G.
    Phelps, H.
    Guest, S.
    Muston, D.
    VALUE IN HEALTH, 2019, 22 : S73 - S74
12345